<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02786485</url>
  </required_header>
  <id_info>
    <org_study_id>BP-008-MUD</org_study_id>
    <nct_id>NCT02786485</nct_id>
  </id_info>
  <brief_title>Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT</brief_title>
  <official_title>A Phase I Study of Matched Unrelated Donor BPX-501 T Cell Infusion for Adults With Recurrent or Minimal Residual Disease Hematologic Malignancies Post-Allogeneic Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bellicum Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bellicum Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I, multicenter, open-label, non-randomized study of matched unrelated donor&#xD;
      BPX-501 T cell infusion in adult subjects with hematological malignancies presenting with&#xD;
      recurrent disease minimal residual disease (MRD) post-allogeneic transplant.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Un-manipulated donor lymphocyte infusion (DLI) is used after stem cell transplantation to&#xD;
      treat and prevent relapse, to prevent infections and to establish full donor chimerism. The&#xD;
      addition of mature T cells which exhibit a broad repertoire of T cell immunity against viral&#xD;
      antigens, as well as against cancer antigens, might provide a clinical benefit. However, an&#xD;
      expected side effect of the presence of mature T cells is the potential occurrence of acute&#xD;
      graft-versus-host disease (aGvHD). The use of a suicide gene switch which would trigger the&#xD;
      initiation of the apoptosis of the alloreactive T cells by the infusion of a drug would&#xD;
      represent the potential optimal strategy for restoring early immunity with a built in &quot;safety&#xD;
      switch&quot; against GvHD side effects. Evidence has emerged that low-dose DLI followed by dose&#xD;
      escalation can achieve higher clinical response rate with lower GvHD occurrence. Optimization&#xD;
      of DLI dose and schedule as well as strategies of donor T-cell manipulation may lead to the&#xD;
      consistent ability to separate GvHD from graft-versus-tumor (GvT) activity and improve the&#xD;
      safety of DLI treatment. Our strategy is to infuse escalating doses of manipulated T cells&#xD;
      (from the same donor who provided the original hematopoietic stem cell graft) in adults and&#xD;
      children with recurrent or minimal residual disease (MRD) hematologic malignancies&#xD;
      post-allogeneic transplant to accelerate immune reconstitution thus improving graft versus&#xD;
      leukemic effect while reducing the severity of GvHD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date type="Actual">May 2016</start_date>
  <completion_date type="Actual">December 2018</completion_date>
  <primary_completion_date type="Actual">December 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>30 days after last dose of study drug (BPX-501 and/or rimiducid)</time_frame>
    <description>Number of adverse events after study drug (BPX-501 and/or rimiducid) administration as a measure of safety</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Lymphomas</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Other High-risk Hematological Malignancies</condition>
  <arm_group>
    <arm_group_label>Rivogenlecleucel &amp; Rimiducid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will receive 3 courses of rivogenlecleucel (BPX-501 T cells) infusions at 30 day intervals with 2 escalating dose levels (DL). DL1 on Day 0 and DL2 on Days 30 and 60.&#xD;
Escalating doses of rimiducid (AP1903) (0.1 mg/kg and 0.4 mg/kg) will be investigated for the treatment of aGvHD after rivogenlecleucel infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rivogenlecleucel</intervention_name>
    <description>T cells transduced with iCasp safety switch</description>
    <arm_group_label>Rivogenlecleucel &amp; Rimiducid</arm_group_label>
    <other_name>BPX-501</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rimiducid</intervention_name>
    <description>administered to treat GVHD</description>
    <arm_group_label>Rivogenlecleucel &amp; Rimiducid</arm_group_label>
    <other_name>AP1903</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects aged ≥ 18 yrs and ≤ 65 yrs;&#xD;
&#xD;
          -  Clinical diagnosis of one of the following hematological malignancies:&#xD;
&#xD;
               -  Leukemia&#xD;
&#xD;
               -  Myelodysplastic Syndromes&#xD;
&#xD;
               -  Lymphomas&#xD;
&#xD;
               -  Multiple Myeloma&#xD;
&#xD;
               -  Other high-risk hematological malignancy eligible for stem cell transplantation&#xD;
                  per institutional standard;&#xD;
&#xD;
          -  Recurrent disease that presents ≥100 days after, or minimal residual disease (MRD)&#xD;
             that presents ≥ 30 days following a hematopoietic stem cell transplant (HSCT) using a&#xD;
             matched unrelated donor located through the National Marrow Donor Program (NMDP);&#xD;
&#xD;
          -  Life expectancy &gt;10 weeks;&#xD;
&#xD;
          -  Signed donor and patient/guardian informed consent;&#xD;
&#xD;
          -  A 8/8 genotypic identical match as determined by high resolution typing for the&#xD;
             following genetic loci: human leukocyte antigen (HLA)-A, HLA-B, HLA-C and HLA-DRB1;&#xD;
&#xD;
          -  Performance status: Karnofsky score &gt; 50%;&#xD;
&#xD;
          -  Subjects with adequate organ function as measured by:&#xD;
&#xD;
               -  Bone marrow:&#xD;
&#xD;
                    -  &gt; 25% donor T-cell chimerism post-transplant&#xD;
&#xD;
                    -  Absolute neutrophil count (ANC) &gt;1 x 109/L&#xD;
&#xD;
               -  Cardiac: left ventricular ejection fraction (LVEF) at rest ≥ 45%&#xD;
&#xD;
               -  Pulmonary: forced expiratory volume (FEV) 1, forced vital capacity (FVC),&#xD;
                  diffusion capacity of lunch for carbon monoxide (DLCO) ≥ 50% predicted (corrected&#xD;
                  for hemoglobin)&#xD;
&#xD;
               -  Hepatic: direct bilirubin ≤ 3x upper limit of normal (ULN), or aspartate&#xD;
                  aminotransferase (AST)/alanine aminotransferase (ALT) ≤ 5x ULN&#xD;
&#xD;
               -  Renal: creatinine ≤ 2x of ULN for age.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  ≥ Grade II acute GVHD or chronic extensive GVHD due to a previous allograft at the&#xD;
             time of screening;&#xD;
&#xD;
          -  Active central nervous system (CNS) involvement with malignant cells (≤ 2 months prior&#xD;
             to consenting);&#xD;
&#xD;
          -  Current uncontrolled bacterial, viral or fungal infection (currently taking medication&#xD;
             with evidence of progression of clinical symptoms or radiologic findings); the&#xD;
             principal investigator is the final arbiter of this criterion;&#xD;
&#xD;
          -  Positive HIV serology or viral RNA;&#xD;
&#xD;
          -  Pregnancy (positive serum β human chorionic gonadotropin [HCG] test) or&#xD;
             breast-feeding;&#xD;
&#xD;
          -  Fertile men or women unwilling to use effective forms of birth control or abstinence&#xD;
             for one year after transplantation;&#xD;
&#xD;
          -  Bovine product allergy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bellicum Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Bellicum Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>May 26, 2016</study_first_submitted>
  <study_first_submitted_qc>May 31, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 1, 2016</study_first_posted>
  <last_update_submitted>October 1, 2020</last_update_submitted>
  <last_update_submitted_qc>October 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BPX-501</keyword>
  <keyword>Rimiducid</keyword>
  <keyword>AP1903</keyword>
  <keyword>Hematological malignancies</keyword>
  <keyword>Hematologic diseases</keyword>
  <keyword>Leukemias and Myelodysplastic Syndromes</keyword>
  <keyword>Lymphomas</keyword>
  <keyword>Multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

